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Abstract: A ﬁ  xed-dose combination of losartan/hydrochlorothiazide (HCTZ) therapy may 
be a logical choice for antihypertensive treatment, including for initial therapy in patients 
with blood pressure elevation >20/10 mmHg above treatment target. The renin–angiotensin–
aldosterone–system-activating effect of hydrochlorothiazide augments the efﬁ  cacy of blocking the 
angiotensin II type 1 (AT1) receptor with losartan. Some adverse effects associated with hydro-
chlorothiazide, including increased risk for new-onset diabetes mellitus, may be offset by losartan. 
Losartan was frequently administered with hydrochlorothiazide in the Losartan Intervention For 
Endpoint reduction in hypertension (LIFE) study, in which there was a 25% risk reduction for stroke 
in the losartan-based compared with the atenolol-based treatment group. The efﬁ  cacy, tolerability, 
and convenience of losartan/HCTZ combination therapy may increase patient compliance and 
lower risk for stroke, a devastating outcome in patients with hypertension.
Keywords: angiotensin receptor blocker, combination therapy, hydrochlorothiazide, 
hypertension, stroke
Introduction to management of stroke risk 
in hypertension
Stroke has enormous consequences for patients and healthcare systems worldwide 
(Goldstein et al 2006). Stroke has been reported to be the most common cardiovas-
cular outcome in many (Kjeldsen et al 2001), but not all (ALLHAT Ofﬁ  cers and 
Coordinators for the ALLHAT Collaborative Research Group 2002), hypertension 
clinical trials. Stroke is the third leading cause of death in the US, with a yearly 
incidence of 700,000 in 2004 and a 1-month fatality rate of about 12% (Rosamond 
et al 2007). Approximately one third of survivors of stroke who have lived for at least 
6 months post-stroke are dependent on others for activities of daily living (Warlow 
1998). The estimated direct and indirect cost of stroke in the US in 2007 is US$62.7 
billion (Rosamond et al 2007).
The predominant modiﬁ  able risk factor for stroke is hypertension (Wolf et al 1991; 
Straus et al 2002). Data from the National Health and Nutrition Examination Survey 
for 1999–2000 (NHANES, n = 4531) showed that the prevalence of hypertension 
in the US is increasing (Fields et al 2004). In 1999–2000, 31.3% of the NHANES 
population had hypertension (blood pressure 140/90 mmHg or treated with antihy-
pertensive therapy) (Fields et al 2004), an increase from the 23.4% prevalence reported 
for 1989–1994 (Wolz et al 2000). This trend was attributed to increased obesity and 
an aging population (Fields et al 2004). In a report from the 1999–2000 NHANES 
population (n = 5448), 58.4% of the participants were treated (an increase of 6.0% 
from 1988–1991), and hypertension was controlled in 31.0% (an increase of 6.4% 
from 1988–1991) (Hajjar and Kotchen 2003). In European countries, the age- and Vascular Health and Risk Management 2007:3(3) 300
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sex-adjusted prevalence of hypertension (140/90 mmHg) 
is 44.2% (vs 27.6% in North America), with an average of 
8% of patients with controlled hypertension (vs 23% in North 
America) (Wolf-Maier et al 2003). 
Current guidelines recommend treatment goals of less 
than 140/90 mmHg for patients with uncomplicated hyperten-
sion and less than 130/80 mmHg for patients with diabetes, 
cardiac disease, or chronic kidney disease (Guidelines 
Committee 2003; Chobanian et al 2003). In clinical trials 
(ALLHAT Ofﬁ  cers and Coordinators for the ALLHAT 
Collaborative Research Group 2002) and clinical practice 
(Amer 2002), most patients require at least two medica-
tions to achieve goal blood pressure. Treatment guidelines 
for hypertension suggest the use of low-dose combination 
agents for the initial treatment of hypertension in some 
circumstances, such as blood pressure elevation greater 
than 20/10 mmHg over goal (Guidelines Committee 2003; 
Chobanian et al 2003).
Here we review the stroke results and losartan plus hydro-
chlorothiazide (HCTZ) use from the Losartan Intervention 
For Endpoint reduction in hypertension (LIFE) study and 
discuss the potential advantages of ﬁ  xed-dose losartan/HCTZ 
therapy for stroke risk reduction.
The LIFE study
Thiazide diuretics and beta-blockers reduce stroke risk in 
patients with hypertension (Mulrow et al 2000; Psaty et al 
2003). In the LIFE study, 9193 patients aged 55–80 with 
hypertension (160–200/95–110 mmHg) and electrocardio-
graphic left ventricular hypertrophy were treated for a mean 
duration of 4.8 years with diuretics for 72% of the time in 
the losartan group and 70% of the time in the atenolol group 
(mean dose of HCTZ in each group was 20 mg) (Dahlöf et al 
1997, 1998, 2004). An independent Endpoint Classiﬁ  cation 
Committee adjudicated endpoints. Stroke (a component of 
the primary composite endpoint that also included cardio-
vascular death and myocardial infarction) was deﬁ  ned as a 
new-onset neurologic deﬁ  cit of vascular origin lasting ≥24 
hours or until death (Kizer et al 2005). Stroke classiﬁ  ca-
tion was based on categories developed in the Framingham 
Study (Wolf et al 1992). Ischemic stroke was assigned in the 
absence of evidence of primary intracranial bleeding, where-
as hemorrhagic stroke required evidence of hemorrhage (ie, 
bloody spinal ﬂ  uid and/or blood on computed tomography), 
excluding cases of vessel rupture due to traumatic, neoplastic, 
or infectious processes. Ischemic stroke was further classiﬁ  ed 
as embolic or athero-thrombotic. The diagnosis of embolic 
stroke was based on the presence of a source of embolus (eg, 
chronic or paroxysmal atrial ﬁ  brillation, rheumatic mitral 
stenosis, recent myocardial infarction, prosthetic heart valve, 
ulcerated carotid plaque) and consistent clinical features 
(eg, rapid onset and partial clearing, slightly bloody spinal 
ﬂ  uid) or the occurrence of associated peripheral emboli. 
Atherothrombotic stroke was assigned when no evidence 
of an embolic etiology was present. Strokes for which a 
distinct etiology could not be ascertained were classiﬁ  ed as 
other. Neurologic deﬁ  cits were classiﬁ  ed as depression of 
consciousness, disturbance of vision, paresis or paralysis 
of one or more extremities, sensory impairment, speech 
impairment, central cranial nerve dysfunction, memory 
defect, ataxia, and movement disorder. 
The primary composite endpoint of cardiovascular 
death, stroke, or myocardial infarction was reduced by 13% 
(p = 0.021) in the losartan group, due primarily to a 25% 
reduction (p = 0.001) in stroke. Kizer et al (2005) examined the 
stroke results in the LIFE study in detail (Table 1). Losartan-
based compared with atenolol-based treatment signiﬁ  cantly 
lowered the risk of fatal stroke by 35% (hazard ratio [HR] 
= 0.65, 95% conﬁ  dence interval [CI] 0.43–0.96, p = 0.032) 
and of atherothrombotic stroke by 27% (HR = 0.73, 95% CI 
0.60–0.89, p = 0.002). The risk reductions for hemorrhagic 
and embolic stroke were 20% and 24%, respectively, but 
these were not statistically signiﬁ  cant, possibly due to low 
numbers. The effect of losartan-based therapy on stroke 
incidence was independent of degree of electrocardiographic 
left ventricular hypertrophy, Framingham risk score, systolic 
blood pressure during follow-up, prevalent and incident 
atrial ﬁ  brillation or coronary heart disease, and treatment 
with aspirin, warfarin, or statins. The risk of recurrent stroke 
was signiﬁ  cantly reduced in the losartan compared with 
the atenolol group (26 versus 46 patients with 2 incident 
strokes, p = 0.017) despite comparable use of antiplatelet 
and/or anticoagulant medications 30 days after the ﬁ  rst 
stroke by 78% of patients in both groups. The number of 
neurologic deﬁ  cits per stroke was similar in both treatment 
groups, but there were fewer strokes in the losartan group 
for virtually every level of stroke severity. The number 
needed to treat for 5 years to prevent one stroke in the 
losartan group as a whole was 54. The numbers needed 
to treat for 5 years to prevent one stroke for patients with 
cerebrovascular disease, isolated systolic hypertension, and 
atrial ﬁ  brillation who were treated with losartan were 25, 
24, and 9, respectively.
Among black patients, greater stroke risk was observed 
in the losartan-based compared with the atenolol-based 
treatment group, which approached statistical signiﬁ  cance Vascular Health and Risk Management 2007:3(3) 301
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(unadjusted HR = 1.99, 95% CI 1.00–3.98, p = 0.051) (Julius 
et al 2004a; Kizer et al 2005). Many American blacks appear 
to have low-renin, salt-sensitive hypertension (Wright 1988) 
and respond less to renin–angiotensin–aldosterone–system 
(RAAS) antihypertensive agents (Hall 1987). However, 
losartan-based and atenolol-based therapy resulted in com-
parable blood-pressure lowering in black and non-black 
subgroups in the LIFE study, and losartan was associated 
with greater left ventricular hypertrophy regression than 
was atenolol in both black and non-black patients (Julius 
et al 2004a). Adjustment for racial differences in baseline 
characteristics did not affect the endpoint results, and changes 
in laboratory measures during the trial were similar in the 
black and non-black subgroups (Julius et al 2004a). Thus, 
there is no apparent explanation for the endpoint results in 
black patients in the LIFE study (Julius et al 2004a). 
Discussion
As early as 1993, it was shown that treatment with losar-
tan at doses that did not affect systolic blood pressure 
decreased the risk of stroke in stroke-prone spontaneously 
hypertensive rats, suggesting that angiotensin II affects 
the pathophysiology of stroke and that losartan has a 
direct stroke beneﬁ  t that is independent of blood pressure 
reduction (Stier et al 1993). These ﬁ  ndings were tested in 
humans in the large, well-conducted LIFE study in which 
losartan-based antihypertensive therapy significantly 
decreased risk for stroke when compared with atenolol-
based therapy in the context of comparable blood pressure 
reductions in both treatment groups (Dahlöf et al 2002). 
Several potential mechanisms that may be responsible 
for the beneﬁ  cial effect of losartan in the LIFE study 
have been suggested (Dahlöf et al 2002; Mancia 2004; 
Devereux and Dahlöf 2007a): attenuation of arterial 
stiffness; inhibition of angiotensin II-induced endothelial 
dysfunction (Schiffrin et al 2000); inhibition of hypertro-
phy, ﬁ  brosis, and remodeling of cerebral arteries; beneﬁ  cial 
effects on concomitant risk factors (albuminuria [Ibsen 
et al 2004], left ventricular hypertrophy [Devereux et al 
2004; Kizer and Devereux 2006; Okin et al 2003], atrial 
fibrillation [Wachtell et al 2005], new-onset diabetes 
[Lindholm et al 2002]); inhibition of platelet aggregation; 
unique molecule-specific effects (eg, uric acid [Hoieggen 
et al 2004]); metabolite-specific anti-inflammatory activ-
ity; and neuro-protective effects (Sadoshima 2002). 
Many patients require more than one antihypertensive 
agent for blood pressure control (ALLHAT Ofﬁ  cers and 
Coordinators for the ALLHAT Collaborative Research 
Group 2002; Amer 2002). Very frequently this includes 
HCTZ because of its antihypertensive efﬁ  cacy, beneﬁ  cial 
effects on stroke (Mulrow et al 2000; Psaty et al 2003), and 
low cost (Chobanian et al 2003). Combining two antihyper-
tensive agents, such as HCTZ and an angiotensin receptor 
blocker (ARB), usually produces additive antihypertensive 
effects. In a meta-analysis of ARB monotherapy and com-
bination therapy with HCTZ (Conlin et al 2000), decreases 
in systolic and diastolic blood pressures were comparable 
for the therapies studied (candesartan, irbesartan, losartan, 
valsartan). The antihypertensive efﬁ  cacy of losartan plus 
HCTZ has been demonstrated in studies of initial/ﬁ  rst-line 
use (Gradman et al 2002; Salerno et al 2004), in patients 
with inadequate blood pressure lowering with losartan mono-
therapy (Gleim et al 2006), and in the LIFE study (Devereux 
et al 2007). A ﬁ  xed-dose combination of losartan/HCTZ 
therapy may be a logical choice for initial therapy in patients 
with blood pressure elevation >20/10 mmHg above treatment 
Table 1 Stroke subtypes by treatment in the LIFE study
Stroke type  Losartan    Atenolol     Adjustedb   Unadjusted 
  (n = 4605)    (n = 4588)    hazard ratio  p-value  hazard ratio   p-value
 n  (%)  Ratea n  (%)  Ratea  (95% CI)    (95% CI)
Any stroke  232 (5.0)  10.8  309 (6.7)  14.5  0.75 (0.63–0.89)  0.001  0.74 (0.63–0.88)  <0.001
Ischemic  203 (4.4)  9.2  277 (6.0)  12.6  0.73 (0.61–0.88)  0.001  0.73 (0.61–0.87)  <0.001
Athero-thrombotic  170 (3.7)  7.9  233 (5.1)  10.9  0.73 (0.60–0.89)  0.002  0.72 (0.59–0.88)  0.001
Embolic  36 (0.8)  1.6  48 (1.0)  2.2  0.76 (0.50–1.18)  0.22  0.75 (0.48–1.15)  0.19
Hemorrhagic  27 (0.6)  1.2  34 (0.7)  1.6  0.80 (0.48–1.32)  0.38  0.79 (0.48–1.31)  0.36
Other/Unclassiﬁ   ed  5  (0.1) 0.2 5  (0.1) 0.2 1.02  (0.30–3.53)  0.97 1.00  (0.29–3.44)  0.99
Any fatal stroke  40 (0.9)  1.8  62 (1.4)  2.8  0.65 (0.43–0.96)  0.032  0.64 (0.43–0.95)  0.028
aPer 1000 patient-years of follow-up.
bFor degree of left ventricular hypertrophy and Framingham risk score at randomization.
Reproduced with permission from Kizer JR et al 2005. Stroke reduction in hypertensive adults with cardiac hypertrophy randomized to losartan versus atenolol. 
The Losartan Intervention For Endpoint Reduction in Hypertension Study. Hypertension, 45:46–52. Copyright © Lippincott Williams & Wilkins.
Abbreviations: CI, conﬁ  dence interval.Vascular Health and Risk Management 2007:3(3) 302
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target (Chobanian et al 2003); this is the only ﬁ  xed-dose 
combination therapy currently approved in the US for the 
treatment of severe hypertension. 
Fixed-dose combinations of HCTZ with ARBs or 
angiotensin-converting enzyme inhibitors (ACEIs) have 
enhanced tolerability (Kjeldsen et al 2005a; Waeber 2003). 
Thiazide diuretics are most effective in patients who have 
salt- or volume-sensitive hypertension. Most patients respond 
to the salt depletion and volume contraction induced by a thia-
zide diuretic by releasing renin (Sassano et al 1989). Blood 
pressure is then more dependent on angiotensin II, and the 
blood pressure effect of diuretics is blunted. Addition of an 
agent that inhibits the RAAS further decreases blood pres-
sure and generally has an additive antihypertensive effect. In 
order for any drug that blocks the RAAS to work optimally, 
high background activity of the system is necessary, a situa-
tion not typical in salt-sensitive hypertension and one that is 
enhanced by treatment with thiazide diuretics (Brunner et al 
1980; Sassano et al 1989) and/or a low-salt diet (Anderson 
and Morgan 1990; MacGregor et al 1987; Navis et al 1987; 
Singer et al 1995). 
There may be better tolerability with a 2-drug combi-
nation of higher doses of ARB/HCTZ compared with a 
multi-drug regimen of lower doses of less well-tolerated 
antihypertensive agents, leading to better patient compliance. 
Many of the undesirable side-effects of thiazide diuretics may 
be lessened by combination with a RAAS agent (Table 2). 
Most importantly, the tendency for thiazides to increase the 
risk for new-onset diabetes during long-term treatment may 
be offset by RAAS antihypertensive agents. Reductions in 
new-onset diabetes with ARBs have been noted with cande-
sartan-based versus placebo-based therapy in the Study on 
Cognition and Prognosis in the Elderly (SCOPE) (Lithell 
et al 2003), losartan-based versus atenolol-based therapy 
in the LIFE study (Dahlöf et al 2002), and valsartan-based 
versus amlodipine-based therapy in the Valsartan Anti-
hypertensive Long-term Use Evaluation (VALUE) study 
(Julius et al 2004b). Reductions in new-onset diabetes with 
ACEIs have been noted with captopril versus diuretics and/or 
beta-blockers in the Captopril Prevention Project (CAPPP) 
(Hansson et al 1999) and ramipril versus placebo therapy in 
the Heart Outcomes Prevention Evaluation (HOPE) study 
(The Heart Outcomes Prevention Evaluation Study Inves-
tigators 2000).
Because of the tendency of RAAS antihypertensive 
agents to increase serum potassium, hypokalemia is likely to 
be less of a problem with diuretics when they are combined 
with RAAS agents (Weinberger 1985). The ARB candesar-
tan did not produce the unfavorable lipid changes of HCTZ 
administered with or without beta-blocker therapy in the 
Antihypertensive Treatment and Lipid Proﬁ  le in a North of 
Sweden Efﬁ  cacy Evaluation (ALPINE) study (Lindholm 
et al 2003). A unique quality of one ARB, losartan, is that it 
lowers serum uric acid (Elliott et al 2001). The increase in 
uric acid that was noted over the course of the LIFE study, 
perhaps partially due to concomitant HCTZ treatment, was 
ameliorated in the losartan-treated group (Hoieggen et al 
2004). This appeared to explain 29% of the beneﬁ  cial treat-
ment effect of losartan on the primary composite endpoint 
of cardiovascular death, stroke, and myocardial infarction, 
raising the possibility that some of the beneﬁ  cial effects of 
losartan in the LIFE study may not be generalizable to the 
ARB class. Uric acid level was an independent predictor of 
stroke in the LIFE study (Kizer et al 2004).
Reducing pill burden has been shown to enhance patients’ 
quality of life and satisfaction and acceptability, adherence, 
and uptake of medications (Dezii 2000; Wald and Law 2003; 
Chapman et al 2005; Sleight et al 2006). Increasing patient 
compliance with antihypertensive therapy is particularly im-
portant in patients at higher risk, such as those with diabetes, 
higher levels of blood pressure, and the metabolic syndrome. 
These patients need multiple medications for treatment of 
concurrent risk factors and conditions (Wald and Law 2003; 
Sleight et al 2006). Furthermore, combination therapy may 
be cost effective because of the potential for reduced drug 
costs (eg, fewer co-payments), better blood pressure con-
trol, improved compliance, and fewer discontinuations and 
switches between therapies (Ambrosioni 2001).
We believe that ARB/HCTZ combinations, such as 
losartan/HCTZ, may be superior to ACEI/HCTZ and other 
antihypertensive agent/HCTZ combinations because of 1) 
the better tolerability of ARBs and 2) available outcomes 
data. Although ramipril compared with placebo therapy 
signiﬁ  cantly lowered the risk for stroke in patients with his-
Table 2 Actions of angiotensin receptor blockers and diuretics
     ARBs+
 ARBs  Diuretics  Diuretics
Antihypertensive effects  ↓  ↓  ↓↓
Renin-angiotensin system  ↓↓  ↑  ↓
Sympathetic nervous system  ↓↓  ↑  ↓
Potassium balance  ↑  ↓ =
Uric acid  ↓ =  ↑ =
Left ventricular hypertrophy  ↓↓  ↓ =  ↓↓
Reproduced with permission from Ram CV.  Angiotensin receptor blockers 
and diuretics as combination therapy: clinical consequences. Am J Hypertens, 
2004;17:277–80. Copyright © 2004 Elsevier. 
Abbreviations: ARB, angiotensin receptor blockerVascular Health and Risk Management 2007:3(3) 303
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tory of cardiovascular disease with or without hypertension 
in the HOPE study (The Heart Outcomes Prevention 
Evaluation Study Investigators 2000), these results that may 
have been inﬂ  uenced by blood pressure differences between 
the groups favoring ramipril as shown in an ambulatory blood 
pressure substudy (Svensson et al 2001). Data from clinical 
trials with ACEIs suggest a neutral effect on outcomes 
compared with traditional antihypertensive treatment for 
the same degree of blood-pressure lowering in patients 
with hypertension and high risk for cardiovascular disease 
(Kjeldsen et al 2005b; Williams 2005). Interestingly, in 
the perindopril protection against recurrent stroke study 
(PROGRESS), which compared single therapy with per-
indopril versus placebo or dual therapy with perindopril 
plus indapamide versus placebo in patients with a history 
of cerebrovascular disease, only combination treatment, 
not the ACEI alone, signiﬁ  cantly reduced stroke incidence 
(PROGRESS Collaborative Group 2001). Data from clinical 
trials suggest that ARBs have beneﬁ  ts on non-coronary 
outcomes compared with traditional treatment; however, 
there have been some inconsistencies in the results of ARB 
trials due to problems with equalizing blood pressures in 
the treatment groups (Kjeldsen et al 2005b). Treatment with 
losartan in the LIFE study was associated with a signiﬁ  cant 
risk reduction for stroke in the context of blood pressure 
reductions similar to those achieved in the active comparator 
(atenolol) group. Similar results were observed for stroke 
or transient ischemic attack in the Morbidity and Mortality 
After Stroke, Eprosartan Compared with Nitrendipine for 
Secondary Prevention (MOSES) study of eprosartan-based 
or nitrendipine-based therapy (Schrader et al 2005). It 
remains to be seen whether comparable advantages will 
be seen with other ARBs compared with other classes of 
antihypertensive drugs in long-term outcome studies. 
Stroke is a devastating outcome in patients with 
hypertension. The efﬁ  cacy, tolerability, and convenience of 
losartan/HCTZ combination therapy may increase patient 
compliance and reduce risk for stroke.
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